NCT01167309View on ClinicalTrials.gov

LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

October 31, 2011

Study Completion Date

December 31, 2011

Conditions
Secondary Hyperparathyroidism
Interventions
DRUG

LEO 27847

First in patient

Trial Locations (2)

24105

CRS Clinical Research Services Kiel GmbH, Kiel

04-141

Centralny Szpital Kliniczny MON, Warsaw

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY